METTL14在非小细胞肺癌中的表达以及预后意义

目的探讨METTL14在非小细胞肺癌(NSCLC)组织中的表达以及与预后之间的相关性。方法收集我院2015年1月-2016年7月收治并行手术切除术的64例NSCLC患者癌变组织(研究组)及相应的癌旁正常组织(对照组),采用实时荧光定量(qRT-PCR)检测组织中METTL14 mRNA的表达,westernblot检测METTL14蛋白表达。比较两组间METTL14的表达与临床病理特征之间的关系,绘制Kaplan-Meier生存曲线,采用多因素Cox回归模型分析独立预后因素。结果METTL14 mRNA在研究组与对照组中的相对表达量分别为(3.03±1.02)、(1.01±0.04),METTL14蛋白在研究组与对照组中的相对表达量分别为(0.21±0.05)、(0.13±0.03),METTL14 mRNA与蛋白在NSCLC癌变组织中的表达较癌旁正常组织高(P均<0.05);TNMⅢ+Ⅳ级、合并淋巴转移的NSCLC患者METTL14高表达的比例较高(P均<0.05),METTL14高、低表达与患者的年龄、性别、病理类型以及吸烟史无关(P均>0.05),METTL14高、低表达的NSCLC患者中位生存时间分别为23.5、34.5个月,总生存率分别为15.63%、46.88%,METTL14低表达的NSCLC患者预后优于METTL14高表达患者(P均<0.05)。Cox回归模型分析发现METTL14高表达、TNMⅢ+Ⅳ级是影响NSCLC患者生存的独立预后因素(P均<0.05)。结论METTL14在NSCLC组织中高表达,且与患者TNM分级、淋巴转移相关,可能参与了NSCLC的发生发展,提示NSCLC患者预后不良。

Expression of METTL14 in non-small cell lung cancer and its prognostic significance

Objective To investigate the expression of METTL14 in non-small cell lung cancer(NSCLC)tissues and its correlation with prognosis.Methods The cancerous tissues(the study group)and corresponding adjacent normal tissues(the control group)of 64 patients with NSCLC who underwent surgical resection of the C-type from January 2015 to July 2016 were collected.Real-time quantitative quantification(qRT-PCR)was used to detect the expression of METTL14 mRNA in tissues,and Western blot was used to detect the expression of METTL14 protein.The expression of METTL14 was compared between the two groups and the high and low expression of METTL14 was defined by the median METTL14 protein expression.The relationship between high and low expression clinicopathological features was analyzed,Kaplan-Meier survival curves were drawn,and independent prognostic factors were analyzed by multivariate Cox regression model.Results The relative expression levels of METTL14 mRNA in the study group and the control group were(3.03±1.02)and(1.01±0.04),and the relative expressions of protein in the study group and the control group were(0.21±0.05)and(0.13±0.03).The expression of METTL14 mRNA and protein in NSCLC cancerous tissues was higher than that in adjacent normal tissues(P<0.05).NSCLC patients with TNMⅢ+IV and lymphatic metastasis had a higher rate of high METTL14 expression(P<0.05).The high and low expression of METTL14 was not associated with the patient s age,gender,pathological type,distant metastasis,and smoking history(P>0.05).The median survival time of patients with high and low expression of METTL14 was 23.5 and 34.5 months,and the overall survival rate was 15.63%and 46.88%,respectively.The prognosis of patients with low expression of METTL14 in NSCLC was superior to those with high METTL14 expression(P<0.05).Cox regression model analysis found that high expression of METTL14 and TNMⅢ+Ⅳwere independent prognostic factors affecting the survival of patients with NSCLC(P<0.05).Conclusion METTL14 is highly expressed in NSCLC tissues and is associated with TNM grade and lymphatic metastasis in patients,and may be involved in the development of NSCLC,suggesting that patients with NSCLC have a poor prognosis.